Osama Albarbarawi

Dr. Osama Albarbarawi

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SPShalini Pathak
Shalini Pathak
VBVladimir S Borodkin
Vladimir S Borodkin
OAOsama Albarbarawi
Osama Albarbarawi
DCDavid G Campbell
David G Campbell
AIAdel Ibrahim
Adel Ibrahim
DADaan MF Van Aalten
Daan MF Van Aalten
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

3 August 2015 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
SPShalini Pathak
Shalini Pathak
JAJana Alonso
Jana Alonso
MSMarianne Schimpl
Marianne Schimpl
KRKarim Rafie
Karim Rafie
DBDavid E Blair
David E Blair
DADaan MF Van Aalten
Daan MF Van Aalten

28 October 2012 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
MSMarianne Schimpl
Marianne Schimpl
XZXiaowei Zheng
Xiaowei Zheng
VBVladimir S Borodkin
Vladimir S Borodkin
DBDavid E Blair
David E Blair
AFAndrew T Ferenbach
Andrew T Ferenbach
DADaan MF Van Aalten
Daan MF Van Aalten
OGT modifies numerous proteins with O-GlcNAc, but the mechanism for this reaction has been difficult to define. Ternary crystal structures and activity assays with substrate analogs now provide evidence that the α-phosphate of the donor substrate is the catalytic base. Protein O-GlcNAcylation is an essential post-translational modification on hundreds of intracellular proteins in metazoa, catalyzed by O-linked β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) using unknown mechanisms of transfer and substrate recognition. Through crystallographic snapshots and mechanism-inspired chemical probes, we define how human OGT recognizes the sugar donor and acceptor peptide and uses a new catalytic mechanism of glycosyl transfer, involving the sugar donor α-phosphate as the catalytic base as well as an essential lysine. This mechanism seems to be a unique evolutionary solution to the spatial constraints imposed by a bulky protein acceptor substrate and explains the unexpected specificity of a recently reported metabolic OGT inhibitor.

16 January 2012 in Thorax
Verified
Journal Article
Open access
PDF file
JHJeffrey T-J Huang
Jeffrey T-J Huang
RCRekha Chaudhuri
Rekha Chaudhuri
OAOsama Albarbarawi
Osama Albarbarawi
ABAlun Barton
Alun Barton
CGChristal Grierson
Christal Grierson
NTNeil C. Thomson
Neil C. Thomson
Background Although an increased concentration of degraded elastin products in patients with chronic obstructive pulmonary disease (COPD) has been reported for many years, its clinical validity and utility remain uncertain due to technical difficulties, small study groups and the unknown relationship between exacerbation and elastin degradation. The objectives of this study were to determine the validity of urinary and blood total desmosine/isodesmosine in patients with COPD and asthma and to evaluate their relationship to exacerbation status and lung function. Methods Urinary and blood desmosine levels were measured using validated isotopic dilution liquid chromatography–tandem mass spectrometry methods. Results 390 study participants were recruited from the following groups: healthy volunteers, stable asthma, stable and ‘during an exacerbation’ COPD. Compared with healthy non-smokers, we found increased urinary or blood desmosine levels in patients with COPD, but no differences in patients with asthma or healthy smokers. The elevation of urinary desmosine levels was associated with the exacerbation status in patients with COPD. Approximately 40% of patients with stable and ‘during an exacerbation’ COPD showed elevated blood desmosine levels. Blood desmosine levels were strongly associated with age and were negatively correlated with lung diffusing capacity for carbon monoxide. Conclusion The results suggest that urinary desmosine levels are raised by exacerbations of COPD whereas blood desmosine levels are elevated in a subgroup of patients with stable COPD and reduced lung diffusing capacity. The authors speculate that a raised blood desmosine level may identify patients with increased elastin degradation suitable for targeted therapy. Future prospective studies are required to investigate this hypothesis.

4 September 2013 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
WFWenxia Fang
Wenxia Fang
TDTing Du
Ting Du
OROlawale G. Raimi
Olawale G. Raimi
RHRamón Hurtado-Guerrero
Ramón Hurtado-Guerrero
KMKarina Valeria Mariño
Karina Valeria Mariño
DADaan MF Van Aalten
Daan MF Van Aalten
Aspergillus fumigatus is the causative agent of IA (invasive aspergillosis) in immunocompromised patients. It possesses a cell wall composed of chitin, glucan and galactomannan, polymeric carbohydrates synthesized by processive glycosyltransferases from intracellular sugar nucleotide donors. Here we demonstrate that A. fumigatus possesses an active AfAGM1 (A. fumigatus N-acetylphosphoglucosamine mutase), a key enzyme in the biosynthesis of UDP (uridine diphosphate)–GlcNAc (N-acetylglucosamine), the nucleotide sugar donor for chitin synthesis. A conditional agm1 mutant revealed the gene to be essential. Reduced expression of agm1 resulted in retarded cell growth and altered cell wall ultrastructure and composition. The crystal structure of AfAGM1 revealed an amino acid change in the active site compared with the human enzyme, which could be exploitable in the design of selective inhibitors. AfAGM1 inhibitors were discovered by high-throughput screening, inhibiting the enzyme with IC50s in the low μM range. Together, these data provide a platform for the future development of AfAGM1 inhibitors with antifungal activity.

2 April 2010 in Analytical Chemistry
Verified
Journal Article
Closed access
OAOsama Albarbarawi
Osama Albarbarawi
ABAlun Barton
Alun Barton
ZLZhaoSheng Lin
ZhaoSheng Lin
ETEddie Takahashi
Eddie Takahashi
ABAjay Buddharaju
Ajay Buddharaju
JHJeffrey T.-J. Huang
Jeffrey T.-J. Huang